Oglufanide

DCTPepD ID  DCTPepD0040

Active Ingredients   Oglufanide

Description  Glu-Trp is a dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage. It has a role as a metabolite, an immunomodulator, an angiogenesis modulating agent and an antineoplastic agent. It is functionally related to a L-glutamic acid and a L-tryptophan.

Synonyms  Glu-trp; Glutamyltryptophan; L-Tryptophan, L-alpha-glutamyl-; Thymogen; Oglufanide

Disease  Colorectal Cancer, Ovarian Cancer, Kaposi's Sarcoma

Classification

  

Immunomodulator Peptide and derivative

Structure Information


Molecular Formula  C16H19N3O5

Molecular Weight  333.34

Active Sequence  EW

Sequence Length  2

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (4S)-4-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid

InChI  InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1

InChI_Key LLEUXCDZPQOJMY-AAEUAGOBSA-N

SMILES  O=C(O)CC[C@H](N)C(N[C@H](C(O)=O)CC1=CNC2=C1C=CC=C2)=O

External Codes


PubChem CID  100094

DrugBank Accession Number  DB05779

NCI Thesaurus Code  C76274  

UNII  4RHY598T5U   GSRS

CAS  38101-59-6



Drug approval


Drug indication
    Investigated for use/treatment in hepatitis (viral, C) and cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00003773 Phase I Study of Escalating Doses of IM-862 in Patients With Ovarian Cancer Ovarian Cancer Phase 1 Treatment
NCT00006037 Phase II Randomized Placebo-Controlled Double-Blinded Study With 5-FU vs. 5-FU With IM862 With Cross-Over to CPT-11 vs. CPT-11 With IM862 Colorectal Cancer Phase 2 Treatment
NCT00017303 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Ovarian Cancer; Primary Peritoneal Cavity Cancer Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.